Literature DB >> 33974106

Natural history, trajectory, and management of mechanically ventilated COVID-19 patients in the United Kingdom.

Brijesh V Patel1,2, Shlomi Haar3,4,5,6, Rhodri Handslip7,8, John R Prowle9, Zudin Puthucheary9, Aldo A Faisal10,11,12,13, Chaiyawan Auepanwiriyakul3,4, Teresa Mei-Ling Lee7,8, Sunil Patel7,8, J Alex Harston3,4, Feargus Hosking-Jervis14, Donna Kelly15, Barnaby Sanderson16, Barbara Borgatta17, Kate Tatham7,18, Ingeborg Welters19, Luigi Camporota16, Anthony C Gordon7,20, Matthieu Komorowski7,20, David Antcliffe7,20.   

Abstract

PURPOSE: The trajectory of mechanically ventilated patients with coronavirus disease 2019 (COVID-19) is essential for clinical decisions, yet the focus so far has been on admission characteristics without consideration of the dynamic course of the disease in the context of applied therapeutic interventions.
METHODS: We included adult patients undergoing invasive mechanical ventilation (IMV) within 48 h of intensive care unit (ICU) admission with complete clinical data until ICU death or discharge. We examined the importance of factors associated with disease progression over the first week, implementation and responsiveness to interventions used in acute respiratory distress syndrome (ARDS), and ICU outcome. We used machine learning (ML) and Explainable Artificial Intelligence (XAI) methods to characterise the evolution of clinical parameters and our ICU data visualisation tool is available as a web-based widget ( https://www.CovidUK.ICU ).
RESULTS: Data for 633 adults with COVID-19 who underwent IMV between 01 March 2020 and 31 August 2020 were analysed. Overall mortality was 43.3% and highest with non-resolution of hypoxaemia [60.4% vs17.6%; P < 0.001; median PaO2/FiO2 on the day of death was 12.3(8.9-18.4) kPa] and non-response to proning (69.5% vs.31.1%; P < 0.001). Two ML models using weeklong data demonstrated an increased predictive accuracy for mortality compared to admission data (74.5% and 76.3% vs 60%, respectively). XAI models highlighted the increasing importance, over the first week, of PaO2/FiO2 in predicting mortality. Prone positioning improved oxygenation only in 45% of patients. A higher peak pressure (OR 1.42[1.06-1.91]; P < 0.05), raised respiratory component (OR 1.71[ 1.17-2.5]; P < 0.01) and cardiovascular component (OR 1.36 [1.04-1.75]; P < 0.05) of the sequential organ failure assessment (SOFA) score and raised lactate (OR 1.33 [0.99-1.79]; P = 0.057) immediately prior to application of prone positioning were associated with lack of oxygenation response. Prone positioning was not applied to 76% of patients with moderate hypoxemia and 45% of those with severe hypoxemia and patients who died without receiving proning interventions had more missed opportunities for prone intervention [7 (3-15.5) versus 2 (0-6); P < 0.001]. Despite the severity of gas exchange deficit, most patients received lung-protective ventilation with tidal volumes less than 8 mL/kg and plateau pressures less than 30cmH2O. This was despite systematic errors in measurement of height and derived ideal body weight.
CONCLUSIONS: Refractory hypoxaemia remains a major association with mortality, yet evidence based ARDS interventions, in particular prone positioning, were not implemented and had delayed application with an associated reduced responsiveness. Real-time service evaluation techniques offer opportunities to assess the delivery of care and improve protocolised implementation of evidence-based ARDS interventions, which might be associated with improvements in survival.

Entities:  

Keywords:  ARDS; Artificial intelligence; COVID-19; Mechanical ventilation; Mortality risk; Prone position

Year:  2021        PMID: 33974106     DOI: 10.1007/s00134-021-06389-z

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  19 in total

1.  Epidemiology, Patterns of Care, and Mortality for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries.

Authors:  Giacomo Bellani; John G Laffey; Tài Pham; Eddy Fan; Laurent Brochard; Andres Esteban; Luciano Gattinoni; Frank van Haren; Anders Larsson; Daniel F McAuley; Marco Ranieri; Gordon Rubenfeld; B Taylor Thompson; Hermann Wrigge; Arthur S Slutsky; Antonio Pesenti
Journal:  JAMA       Date:  2016-02-23       Impact factor: 56.272

2.  Visualization of SARS-CoV-2 in the Lung. Reply.

Authors:  Maximilian Ackermann; Steven J Mentzer; Danny Jonigk
Journal:  N Engl J Med       Date:  2020-12-31       Impact factor: 91.245

3.  Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial.

Authors:  Caicun Zhou; Gongyan Chen; Yunchao Huang; Jianying Zhou; LiZhu Lin; Jifeng Feng; Zhehai Wang; Yongqian Shu; Jianhua Shi; Yi Hu; QiMing Wang; Ying Cheng; Fengying Wu; Jianhua Chen; Xiaoyan Lin; Yongsheng Wang; Jianan Huang; Jiuwei Cui; Lejie Cao; Yunpeng Liu; Yiping Zhang; Yueyin Pan; Jun Zhao; LiPing Wang; Jianhua Chang; Qun Chen; Xiubao Ren; Wei Zhang; Yun Fan; Zhiyong He; Jian Fang; Kangsheng Gu; XiaoRong Dong; Tao Zhang; Wei Shi; Jianjun Zou
Journal:  Lancet Respir Med       Date:  2020-12-18       Impact factor: 30.700

4.  Patterns of Use of Adjunctive Therapies in Patients With Early Moderate to Severe ARDS: Insights From the LUNG SAFE Study.

Authors:  Abhijit Duggal; Emanuele Rezoagli; Tài Pham; Bairbre A McNicholas; Eddy Fan; Giacomo Bellani; Gordon Rubenfeld; Antonio M Pesenti; John G Laffey
Journal:  Chest       Date:  2020-02-20       Impact factor: 9.410

5.  Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes.

Authors:  Daniel E Leisman; Lukas Ronner; Rachel Pinotti; Matthew D Taylor; Pratik Sinha; Carolyn S Calfee; Alexandre V Hirayama; Fiore Mastroiani; Cameron J Turtle; Michael O Harhay; Matthieu Legrand; Clifford S Deutschman
Journal:  Lancet Respir Med       Date:  2020-10-16       Impact factor: 30.700

6.  Ventilation management and clinical outcomes in invasively ventilated patients with COVID-19 (PRoVENT-COVID): a national, multicentre, observational cohort study.

Authors:  Michela Botta; Anissa M Tsonas; Janesh Pillay; Leonoor S Boers; Anna Geke Algera; Lieuwe D J Bos; Dave A Dongelmans; Marcus W Hollmann; Janneke Horn; Alexander P J Vlaar; Marcus J Schultz; Ary Serpa Neto; Frederique Paulus
Journal:  Lancet Respir Med       Date:  2020-10-23       Impact factor: 30.700

7.  Response to COVID-19 phenotyping correspondence.

Authors:  Lieuwe D J Bos; Pratik Sinha; Robert P Dickson
Journal:  Eur Respir J       Date:  2020-08-27       Impact factor: 16.671

8.  Extracorporeal membrane oxygenation support in COVID-19: an international cohort study of the Extracorporeal Life Support Organization registry.

Authors:  Ryan P Barbaro; Graeme MacLaren; Philip S Boonstra; Theodore J Iwashyna; Arthur S Slutsky; Eddy Fan; Robert H Bartlett; Joseph E Tonna; Robert Hyslop; Jeffrey J Fanning; Peter T Rycus; Steve J Hyer; Marc M Anders; Cara L Agerstrand; Katarzyna Hryniewicz; Rodrigo Diaz; Roberto Lorusso; Alain Combes; Daniel Brodie
Journal:  Lancet       Date:  2020-09-25       Impact factor: 79.321

9.  Overcoming bleeding events related to extracorporeal membrane oxygenation in COVID-19 - Authors' reply.

Authors:  Matthieu Schmidt; Juliette Chommeloux; Corinne Frere; Guillaume Hekimian; Alain Combes
Journal:  Lancet Respir Med       Date:  2020-10-29       Impact factor: 30.700

10.  Pathophysiology of COVID-19-associated acute respiratory distress syndrome - Authors' reply.

Authors:  Giacomo Grasselli; Tommaso Tonetti; Claudia Filippini; Arthur S Slutsky; Antonio Pesenti; V Marco Ranieri
Journal:  Lancet Respir Med       Date:  2020-11-13       Impact factor: 30.700

View more
  19 in total

Review 1.  Nutritional priorities in patients with severe COVID-19.

Authors:  Zudin A Puthucheary; Todd W Rice
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2022-07-01       Impact factor: 3.620

2.  If not now, when? A clinical perspective on the unprecedented challenges facing ICUs during the COVID-19 pandemic.

Authors:  Ignacio Martin-Loeches; Yaseen Arabi; Giuseppe Citerio
Journal:  Intensive Care Med       Date:  2021-05-11       Impact factor: 17.440

Review 3.  Pathophysiology of coronavirus-19 disease acute lung injury.

Authors:  Luigi Camporota; John N Cronin; Mattia Busana; Luciano Gattinoni; Federico Formenti
Journal:  Curr Opin Crit Care       Date:  2022-02-01       Impact factor: 3.687

4.  Visualizing in deceased COVID-19 patients how SARS-CoV-2 attacks the respiratory and olfactory mucosae but spares the olfactory bulb.

Authors:  Mona Khan; Seung-Jun Yoo; Marnick Clijsters; Wout Backaert; Arno Vanstapel; Kato Speleman; Charlotte Lietaer; Sumin Choi; Tyler D Hether; Lukas Marcelis; Andrew Nam; Liuliu Pan; Jason W Reeves; Pauline Van Bulck; Hai Zhou; Marc Bourgeois; Yves Debaveye; Paul De Munter; Jan Gunst; Mark Jorissen; Katrien Lagrou; Natalie Lorent; Arne Neyrinck; Marijke Peetermans; Dietmar Rudolf Thal; Christophe Vandenbriele; Joost Wauters; Peter Mombaerts; Laura Van Gerven
Journal:  Cell       Date:  2021-11-03       Impact factor: 41.582

Review 5.  Complications of Critical COVID-19: Diagnostic and Therapeutic Considerations for the Mechanically Ventilated Patient.

Authors:  David M Maslove; Stephanie Sibley; J Gordon Boyd; Ewan C Goligher; Laveena Munshi; Isaac I Bogoch; Bram Rochwerg
Journal:  Chest       Date:  2021-10-13       Impact factor: 10.262

6.  Effect of Vitamin C on Clinical Outcomes of Critically Ill Patients With COVID-19: An Observational Study and Subsequent Meta-Analysis.

Authors:  Evdokia Gavrielatou; Eleni Xourgia; Nikoleta A Xixi; Athina G Mantelou; Eleni Ischaki; Aggeliki Kanavou; Dimitris Zervakis; Christina Routsi; Anastasia Kotanidou; Ilias I Siempos
Journal:  Front Med (Lausanne)       Date:  2022-02-11

7.  Prevalence, characteristics, and longer-term outcomes of patients with persistent critical illness attributable to COVID-19 in Scotland: a national cohort study.

Authors:  Michael C Blayney; Neil I Stewart; Callum T Kaye; Kathryn Puxty; Robert Chan Seem; Lorraine Donaldson; Catriona Haddow; Ros Hall; Caroline Martin; Martin Paton; Nazir I Lone; Joanne McPeake
Journal:  Br J Anaesth       Date:  2022-03-24       Impact factor: 11.719

8.  Prone Position in COVID-19 and -COVID-19 Acute Respiratory Distress Syndrome: An International Multicenter Observational Comparative Study.

Authors:  Luigi Camporota; Barnaby Sanderson; Davide Chiumello; Nicolas Terzi; Laurent Argaud; Thomas Rimmelé; Romain Metuor; Aude Verstraete; Martin Cour; Julien Bohé; Vincent Piriou; Pascal Beuret; Claude Guérin
Journal:  Crit Care Med       Date:  2022-04-01       Impact factor: 9.296

9.  Diagnostic accuracy of three commercially available one step RT-PCR assays for the detection of SARS-CoV-2 in resource limited settings.

Authors:  Abay Sisay; Adugna Abera; Boja Dufera; Tujuba Endrias; Geremew Tasew; Abraham Tesfaye; Sonja Hartnack; Dereje Beyene; Adey Feleke Desta
Journal:  PLoS One       Date:  2022-01-20       Impact factor: 3.240

10.  Time course of risk factors associated with mortality of 1260 critically ill patients with COVID-19 admitted to 24 Italian intensive care units.

Authors:  Alberto Zanella; Gaetano Florio; Massimo Antonelli; Giacomo Bellani; Angela Berselli; Tiziana Bove; Luca Cabrini; Eleonora Carlesso; Gian Paolo Castelli; Maurizio Cecconi; Giuseppe Citerio; Irene Coloretti; Daniele Corti; Francesca Dalla Corte; Edoardo De Robertis; Giuseppe Foti; Roberto Fumagalli; Massimo Girardis; Riccardo Giudici; Lorenzo Guiotto; Thomas Langer; Lucia Mirabella; Daniela Pasero; Alessandro Protti; Marco V Ranieri; Roberto Rona; Luigia Scudeller; Paolo Severgnini; Savino Spadaro; Nino Stocchetti; Martina Viganò; Antonio Pesenti; Giacomo Grasselli
Journal:  Intensive Care Med       Date:  2021-08-09       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.